Q2 2026 Boston Scientific Corp Earnings Call Transcript
Key Points
- Boston Scientific Corp (BSX) reported a solid second quarter with organic sales growth of 7%, driven by strong performance in Interventional Cardiology, Endoscopy, and Neuromodulation.
- The company exceeded its adjusted EPS guidance range with a 15% growth, reaching $0.86, primarily due to favorable tax results.
- Neuromodulation sales grew 12%, with double-digit growth in both pain and brain segments, supported by successful integration of Nalu.
- Interventional Cardiology business achieved 15% growth, driven by double-digit growth in coronary therapies and strong performance in DCB, Imaging, and Complex PCI.
- Boston Scientific Corp (BSX) announced a restructuring program aimed at delivering approximately $500 million in run rate savings by 2029, enabling sustainable cost efficiencies and strategic reinvestment.
- The company updated its full-year 2026 guidance, expecting more pressure in the second half than originally anticipated, with organic revenue growth revised to 5% to 6%.
- WATCHMAN sales growth slowed sharply due to compounding clinical evidence impacting referral patterns, leading to a revised outlook of flat to low single-digit growth for the full year.
- Electrophysiology (EP) faced unexpected competitive pressures in the US market, resulting in a revised outlook of flat growth for the second half of 2026.
- Urology sales grew only 1%, falling short of expectations due to slower recovery in sacral neuromodulation and market pressure in stone management.
- Cardiac Rhythm Management sales declined 2% in the quarter, with competitive pressure and portfolio gaps impacting performance.
Good morning, and welcome to the Boston Scientific second quarter 2026 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations.
Thank you, [Drew], and thanks to everyone for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Jon will be joined by our Chief Medical Officer, Dr. Ken Stein.
We issued a press release earlier this morning announcing our Q2 2026 results, which included reconciliations of the non-GAAP measures used in this release. The release as well as the reconciliations of non-GAAP measures used in today's call can be found on the Investor Relations section of our website.
Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
